Strategic Investment Advisors MI Acquires New Position in Boston Scientific Corporation $BSX

Strategic Investment Advisors MI bought a new position in shares of Boston Scientific Corporation (NYSE:BSX) during the 1st quarter, HoldingsChannel.com reports. The fund bought 13,808 shares of the medical equipment provider’s stock, valued at approximately $812,000.

A number of other hedge funds also recently added to or reduced their stakes in BSX. FWL Investment Management LLC acquired a new position in shares of Boston Scientific in the second quarter worth $26,000. Swiss RE Ltd. acquired a new stake in shares of Boston Scientific in the fourth quarter valued at $26,000. Garton & Associates Financial Advisors LLC purchased a new position in Boston Scientific in the fourth quarter valued at $26,000. Bangor Savings Bank boosted its holdings in Boston Scientific by 94.7% in the fourth quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock valued at $28,000 after purchasing an additional 142 shares during the period. Finally, Clal Insurance Enterprises Holdings Ltd acquired a new position in Boston Scientific during the 1st quarter worth $28,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Boston Scientific Trading Down 0.3%

NYSE BSX opened at $45.92 on Friday. The firm’s fifty day moving average price is $46.35 and its 200 day moving average price is $62.37. Boston Scientific Corporation has a 12 month low of $42.20 and a 12 month high of $109.50. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.22. The company has a market capitalization of $68.25 billion, a price-to-earnings ratio of 18.59, a price-to-earnings-growth ratio of 0.89 and a beta of 0.58.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, beating analysts’ consensus estimates of $0.83 by $0.03. Boston Scientific had a net margin of 17.50% and a return on equity of 19.36%. The firm had revenue of $5.44 billion during the quarter, compared to analysts’ expectations of $5.38 billion. During the same period in the previous year, the company earned $0.75 earnings per share. Boston Scientific’s quarterly revenue was up 7.5% compared to the same quarter last year. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, sell-side analysts expect that Boston Scientific Corporation will post 3.31 earnings per share for the current fiscal year.

Boston Scientific declared that its Board of Directors has initiated a share repurchase program on Monday, May 18th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the medical equipment provider to purchase up to 6.4% of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s management believes its stock is undervalued.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the company. Citigroup cut their price target on Boston Scientific from $70.00 to $61.00 and set a “buy” rating on the stock in a report on Thursday. Bank of America decreased their price objective on Boston Scientific from $105.00 to $68.00 and set a “buy” rating for the company in a research note on Monday, May 18th. The Goldman Sachs Group set a $71.00 price objective on Boston Scientific in a research report on Thursday, May 28th. Jefferies Financial Group reduced their target price on shares of Boston Scientific from $100.00 to $67.00 and set a “buy” rating on the stock in a report on Wednesday, June 24th. Finally, Weiss Ratings downgraded shares of Boston Scientific from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Tuesday, July 7th. One analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $71.62.

Boston Scientific News Roundup

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Second-quarter results exceeded expectations. Boston Scientific reported revenue of $5.442 billion, up 7.5% year over year, and adjusted earnings of $0.86 per share versus the $0.83 consensus estimate. Cardiovascular sales increased 8.3%, while international growth was particularly strong in APAC and LACA. Boston Scientific announces results for second quarter 2026
• Positive Sentiment: Cost savings and product development may support longer-term growth. Boston Scientific is pursuing a multiyear restructuring program targeting approximately $500 million in annual savings, received FDA clearance for its TruSelect 2.6 Microcatheter and invested $1.5 billion in MiRus, including an option to acquire its TAVR business. The company also completed a $2 billion accelerated share repurchase.
• Positive Sentiment: Analysts remain broadly bullish despite lower targets. TD Cowen, Truist and BTIG retained “buy” ratings, while UBS reaffirmed its “buy” rating. However, their price targets were reduced to reflect more cautious near-term assumptions. What Are Wall Street Analysts’ Target Price for Boston Scientific Stock?
• Neutral Sentiment: Boston Scientific is acquiring Penumbra. Penumbra reported second-quarter revenue of $390.0 million, up 14.9%, with gross margin improving to 67.9%. The company will not provide full-year guidance or hold a conference call because of the pending acquisition by Boston Scientific. The deal could expand BSX’s thrombectomy and embolization portfolio, but integration and transaction costs remain factors for investors. Penumbra, Inc. Reports Second Quarter 2026 Financial Results
• Negative Sentiment: Lower guidance overshadowed the quarterly beat. Boston Scientific now expects full-year adjusted EPS of $3.28–$3.32, below the prior $3.34–$3.41 range and analyst expectations of roughly $3.36. Third-quarter EPS and revenue guidance also fell short of consensus.
• Negative Sentiment: WATCHMAN and electrophysiology headwinds are weighing on expectations. Softer WATCHMAN demand, competition and slower EP growth prompted management to temper its outlook. The company also faces a product recall and expects restructuring costs of approximately $700 million to $800 million through 2029. Boston Scientific trims annual profit forecast on softer Watchman device demand

Insider Activity

In other news, Director Edward J. Ludwig bought 3,580 shares of Boston Scientific stock in a transaction dated Wednesday, May 20th. The stock was acquired at an average cost of $56.68 per share, with a total value of $202,914.40. Following the acquisition, the director owned 25,359 shares of the company’s stock, valued at approximately $1,437,348.12. This trade represents a 16.44% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Cheryl Pegus bought 1,770 shares of the firm’s stock in a transaction that occurred on Wednesday, May 20th. The stock was purchased at an average cost of $56.49 per share, with a total value of $99,987.30. Following the completion of the transaction, the director owned 1,770 shares in the company, valued at approximately $99,987.30. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders bought 9,800 shares of company stock valued at $554,012. Insiders own 0.34% of the company’s stock.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.